Clinical neuropharmacology
-
Clin Neuropharmacol · Jan 2011
Randomized Controlled Trial Multicenter StudyA 52-week study of gabapentin enacarbil in restless legs syndrome.
This open-label, multicenter, 52-week extension study (NCT00333359) assessed the long-term safety and efficacy of gabapentin enacarbil in subjects with moderate-to-severe primary restless legs syndrome (RLS). ⋯ Gabapentin enacarbil was generally safe and well tolerated and improved RLS symptoms in subjects with moderate-to-severe primary RLS for up to 64 weeks of treatment.